News
Pacira BioSciences boasts a strong balance sheet with $495 million in cash and a new $300 million stock buyback authorization ...
Panelists discuss updated MonumenTAL-1 trial data demonstrating high response rates and prolonged survival with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback